NASDAQ:ANIKAnika Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anika Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.17 -0.92 (-3.16 %) (As of 04/7/2020 03:08 PM ET) Add Compare Share Today's Range$28.10Now: $28.17▼$30.8250-Day Range$22.38MA: $35.04▼$43.0652-Week Range$22.01Now: $28.17▼$75.71Volume7,141 shsAverage Volume226,683 shsMarket Capitalization$399.17 millionP/E Ratio14.83Dividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.75, Anika Therapeutics has a potential upside of 90.8% from its current price of $28.17.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAnika Therapeutics has received 281 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnika Therapeutics has received 275 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnika Therapeutics has received 50.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote “Outperform” if you believe ANIK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $115,236.00 in company stock.Percentage Held by InsidersOnly 3.67% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions96.38% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow by 34.29% in the coming year, from $1.40 to $1.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is 14.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is 14.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.59.Price to Earnings Growth RatioAnika Therapeutics has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK Previous Symbol CUSIP03525510 CIK898437 Webhttp://www.anikatherapeutics.com/ Phone781-457-9000Debt Debt-to-Equity Ratio0.07 Current Ratio14.40 Quick Ratio13.04Price-To-Earnings Trailing P/E Ratio14.83 Forward P/E Ratio20.12 P/E Growth1.99 Sales & Book Value Annual Sales$114.51 million Price / Sales3.49 Cash Flow$2.54 per share Price / Cash Flow11.09 Book Value$20.21 per share Price / Book1.39Profitability EPS (Most Recent Fiscal Year)$2.05 Net Income$27.19 million Net Margins23.73% Return on Equity10.81% Return on Assets9.47%Miscellaneous Employees133 Outstanding Shares14,170,000Market Cap$399.17 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive ANIK News and Ratings via Email Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ANIK Rates by TradingView Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK shares have decreased by 22.6% and is now trading at $28.17. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Anika Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Anika Therapeutics. When is Anika Therapeutics' next earnings date? Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Anika Therapeutics. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, February, 20th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.02. The biotechnology company had revenue of $29.77 million for the quarter, compared to analyst estimates of $27.63 million. Anika Therapeutics had a net margin of 23.73% and a return on equity of 10.81%. View Anika Therapeutics' earnings history. What guidance has Anika Therapeutics issued on next quarter's earnings? Anika Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $160-165 million, compared to the consensus revenue estimate of $138.97 million. What price target have analysts set for ANIK? 4 brokerages have issued 12-month price objectives for Anika Therapeutics' stock. Their forecasts range from $29.00 to $65.00. On average, they expect Anika Therapeutics' stock price to reach $53.75 in the next year. This suggests a possible upside of 90.8% from the stock's current price. View analysts' price targets for Anika Therapeutics. What are Wall Street analysts saying about Anika Therapeutics stock? Here are some recent quotes from research analysts about Anika Therapeutics stock: 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (2/24/2020) 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019) Has Anika Therapeutics been receiving favorable news coverage? Media headlines about ANIK stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAnika Therapeutics. Who are some of Anika Therapeutics' key competitors? Some companies that are related to Anika Therapeutics include Cooper Companies (COO), Align Technology (ALGN), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Quidel (QDEL), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Antares Pharma (ATRS). What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Gilead Sciences (GILD), Celgene (CELG), CVS Health (CVS), AT&T (T), Broadcom (AVGO), Ligand Pharmaceuticals (LGND), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Amgen (AMGN). Who are Anika Therapeutics' key executives? Anika Therapeutics' management team includes the following people: Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)Mr. Alexei Goraltchouk, VP of Operations What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View institutional ownership trends for Anika Therapeutics. Which major investors are buying Anika Therapeutics stock? ANIK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View insider buying and selling activity for Anika Therapeutics. How do I buy shares of Anika Therapeutics? Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $28.17. How big of a company is Anika Therapeutics? Anika Therapeutics has a market capitalization of $399.17 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe. View additional information about Anika Therapeutics. What is Anika Therapeutics' official website? The official website for Anika Therapeutics is http://www.anikatherapeutics.com/. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is Net Asset Value (NAV)?
